The Supreme Cannabis Company (TSXV:FIRE) smashed its previous records with the release of its financial and operating results for Q1 2019 on Wednesday (November 14), which saw a revenue spike of 229 percent from Q1 2018 to C$5.14 million.

Alongside the year-on-year growth was a 45 percent increase from the previous quarter, which came in at C$3.55 million. While the company’s losses were also up, hitting C$5.39 million versus Q1 2018’s C$2.18 million, Supreme attributed some of the positive results to its flagship cannabis brand, 7ACRES.

“Q1 2019 results are continued validation for the successful execution of our strategy for our 7ACRES business to establish a competitive advantage in quality driven regulated cultivation at scale,” Navdeep Dhaliwal, CEO of Supreme, said in the press release.

“We’ve established valuable intellectual property and laid a strong foundation for 2019 by amassing coast-to-coast distribution for what we believe is the only premium High-End Cannabis™ grown at scale in the country. Moving forward, our branding and distribution for 7ACRES will accelerate, as we’re confident that consumers will further fuel our growth as they recognize the standard 7ACRES has set in the market for premium dried flower.”

The company saw a busy quarter through expansion plans and supply agreements; in early September, Supreme was approved for additional production capacity at its 7ACRES facility.

Health Canada greenlit the company’s plans to add 20,000 square feet of flowering rooms, bringing total capacity to 90,000 square feet and boosting annual production potential from 10,000 kilograms (kg) to 13,330 kg. The company expects the flowering rooms to be completed in December 2018.

Later that month, Supreme signed a 12-month guaranteed supply agreement for 7ACRES dried cannabis with Tilray (NASDAQ:TLRY). The deal, which has an estimated value of C$12 million, began as of October 1 to support medical cannabis patients in Canada.

Supreme also signed agreements with six Canadian provinces during this quarter to help supply the legal adult-use market following legalization.

Supreme shares were down 5.75 percent on the TSX Venture Exchange as of 12:15 p.m. EST on November 14, hitting C$1.64 a stock. On TradingView, shares of the company are currently ranked as a “Sell,” with 15 against, 9 “Neutral” and two as a “Buy.”

Don’t forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Supreme Cannabis Company is a client of the Investing News Network. This article is not paid-for content.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less